Group 1 - Becton, Dickinson and Company (BDX) is recognized as a medical technology company currently undergoing a turnaround due to past challenges, including strategic missteps and a significant product recall [2][3] - The company has acquired the critical care product group from Edwards Lifesciences to enhance its core business and plans to spin off its biosciences and diagnostic solutions division, which is set to be purchased by Waters in a deal expected to close by 2026 [3] - BDX has a strong dividend history, with a 53-year track record of consistent payments, offering a quarterly dividend of $1.04 per share and a dividend yield of 2.22% as of September 19 [5] Group 2 - The planned spinoff of the biosciences and diagnostic solutions division is projected to be accretive to earnings in its first year, suggesting that the dividend should remain stable throughout the transition [4]
Becton, Dickinson and Company (BDX): A Healthcare Leader Among Cheap Dividend Stocks